



## Clinical trial results:

### Immunogenicity and Safety of a Purified Vero Rabies Vaccine - Serum Free in Comparison With Verorab® and Imovax® Rabies, in a Pre-exposure Regimen in Both Pediatric and Adult Populations and a Single Booster Dose of Purified Vero Rabies Vaccine - Serum Free Administered at 1 Year Post-3-dose Primary Series, and Between 2 up to 3 Years Post-One Week 2-Dose Primary Series in a Subset of Adults in Thailand

#### Summary

EudraCT number	2019-000973-22
Trial protocol	Outside EU/EEA
Global end of trial date	24 April 2025

#### Results information

Result version number	v2 (current)
This version publication date	26 October 2025
First version publication date	02 August 2024
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	VRV12
-----------------------	-------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04127786
WHO universal trial number (UTN)	U1111-1217-3241
Other trial identifiers	EudraCT: 2019-000973-22

Notes:

#### Sponsors

Sponsor organisation name	Sanofi Pasteur
Sponsor organisation address	14 Espace Henry Vallée, Lyon, France, 69007
Public contact	Trial Transparency Team, Sanofi Pasteur, Contact-US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi Pasteur, Contact-US@sanofi.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-002234-PIP01-17
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes
--	-----

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 June 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	24 April 2025
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To demonstrate that Purified Vero Rabies Vaccine – Serum Free (VRVg)-2 was non-inferior to Verorab and Imovax Rabies vaccines in each age group (pediatric and adult populations) when administered as a 3-dose pre-exposure prophylaxis (PrEP) regimen, in terms of proportion of subjects achieving an Rabies virus neutralizing antibody (RVNA) titer  $\geq 0.5$  International units per milliliter (IU/mL) at D42, ie, 14 days after the 3rd injection (for Primary Series Cohort 1).

Protection of trial subjects:

Subjects were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time in language and terms appropriate for the subject and considering the local culture. During the course of the trial, subjects were provided with individual subject cards indicating the nature of the trial the subject is participating, contact details and any information needed in the event of a medical emergency.

Collected personal data and human biological samples were processed in compliance with the Sanofi Aventis Group Personal Data Protection Charter ensuring that the Group abides by the laws governing personal data protection in force in all countries in which it operates.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	21 October 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Thailand: 1708
Worldwide total number of subjects	1708
EEA total number of subjects	0

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	21
Children (2-11 years)	336
Adolescents (12-17 years)	148
Adults (18-64 years)	1182
From 65 to 84 years	21
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

1708 participants were enrolled in the study from 21-Oct-2019 to 23-Jan-2023. Study had 2 phases: Primary series (Cohort (C)-1: 3-dose PrEP regimen & C-2: 1-week 2-dose PrEP regimen); & Booster Phase (C-1: booster dose 1 year after 1st primary series vaccine injection & C-2: Immunogenicity Persistence & Booster Phase C-2).

### Pre-assignment

Screening details:

The analysis contains all data in the primary series and booster phase of Cohort-1 and Cohort-2.

### Period 1

Period 1 title	Primary Series
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

The study was conducted in an observer-blind manner for cohort 1 primary series and cohort 2 primary series. Unblinded staff members, independent of the safety evaluation and other study evaluations, prepared and administered the vaccine. The Investigator or delegate in charge of safety assessment as well as the participants were blinded and did not know which vaccine was administered. Laboratory analysts for the blood sample testing remain blinded during the whole study.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort-1 Group 1: VRVg-2

Arm description:

Pediatric and adult participants received a total of 3 intramuscular (IM) injections of Purified Vero Rabies Vaccine – Serum Free (VRVg-2) in the primary series (1 injection each on Day 0, Day 7, and Day 28).

Arm type	Experimental
Investigational medicinal product name	VRVg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

The investigational product is VRVg and VRVg-2 was the formulation used. A dose of 0.5 mL VRVg-2 was administered as intramuscular (IM) injection into the deltoid muscle (or anterolateral thigh for toddlers).

<b>Arm title</b>	Cohort-1 Group 2: Verorab®
------------------	----------------------------

Arm description:

Pediatric and adult participants received a total of 3 IM injections of Verorab® vaccine in the primary series (1 injection each on Day 0, Day 7, and Day 28).

Arm type	Active comparator
Investigational medicinal product name	Verorab®
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

A dose of 0.5 mL Verorab® was administered as IM injection into the deltoid muscle (or anterolateral thigh for toddlers).

<b>Arm title</b>	Cohort-1 Group 3: Imovax Rabies®
Arm description: Pediatric and adult participants received a total of 3 IM injections of Imovax Rabies® vaccine in the primary series (1 injection each on Day 0, Day 7, and Day 28).	
Arm type	Active comparator
Investigational medicinal product name	Imovax® Rabies
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details: A dose of 1 mL Imovax® Rabies was administered as IM injection into the deltoid muscle (or anterolateral thigh for toddlers).	
<b>Arm title</b>	Cohort-2 Group 4: VRVg-2
Arm description: Adult participants received a total of 2 IM injections of VRVg-2 vaccine in the primary series (1 injection each on Day 0 and Day 7).	
Arm type	Experimental
Investigational medicinal product name	VRVg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details: The investigational product is VRVg and VRVg-2 was the formulation used. A dose of 0.5 mL VRVg-2 was administered as IM injection into the deltoid muscle (or anterolateral thigh for toddlers).	
<b>Arm title</b>	Cohort-2 Group 5: Verorab®
Arm description: Adult participants received a total of 2 IM injections of Verorab® vaccine in the primary series (1 injection each on Day 0 and Day 7).	
Arm type	Active comparator
Investigational medicinal product name	Verorab®
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details: A dose of 0.5 mL Verorab® was administered as IM injection into the deltoid muscle (or anterolateral thigh for toddlers).	
<b>Arm title</b>	Cohort-2 Group 6: Imovax Rabies®
Arm description: Adult participants received a total of 2 IM injections of Imovax Rabies® vaccine in the primary series (1 injection each on Day 0 and Day 7).	
Arm type	Active comparator
Investigational medicinal product name	Imovax® Rabies
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use
Dosage and administration details: A dose of 1 mL Imovax® Rabies was administered as IM injection into the deltoid muscle (or anterolateral thigh for toddlers).	

Number of subjects in period 1	Cohort-1 Group 1: VRVg-2	Cohort-1 Group 2: Verorab®	Cohort-1 Group 3: Imovax Rabies®
Started	607	203	200
Safety analysis set (SafAS)	607	202	200
PPAS for Day 28	519 <sup>[1]</sup>	169 <sup>[2]</sup>	160 <sup>[3]</sup>
Completed	599	199	196
Not completed	8	4	4
Consent withdrawn by subject	-	-	-
Adverse event, non-fatal	1	-	-
Withdrawal by Parent/Guardian	2	1	-
Protocol deviation	5	3	4

Number of subjects in period 1	Cohort-2 Group 4: VRVg-2	Cohort-2 Group 5: Verorab®	Cohort-2 Group 6: Imovax Rabies®
Started	420	139	139
Safety analysis set (SafAS)	419	139	139
PPAS for Day 28	342 <sup>[4]</sup>	120 <sup>[5]</sup>	124 <sup>[6]</sup>
Completed	415	137	138
Not completed	5	2	1
Consent withdrawn by subject	1	-	-
Adverse event, non-fatal	1	-	1
Withdrawal by Parent/Guardian	-	-	-
Protocol deviation	3	2	-

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: This PPAS for Day 28 included all the participants in primary series Cohort 1 Group 1 who completed the 2-dose vaccination schedule with VRVg-2 (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: This PPAS for Day 28 included all the participants in primary series Cohort 1 Group 2 who completed the 2-dose vaccination schedule with Verorab® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: This PPAS for Day 28 included all the participants in primary series Cohort 1 Group 3 who completed the 2-dose vaccination schedule with Imovax Rabies® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 4 who completed the 2-dose vaccination schedule with VRVg-2 (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 5 who completed the 2-dose vaccination schedule with Verorab® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 6 who completed the 2-dose vaccination schedule with Imovax Rabies® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).

## Period 2

Period 2 title	Booster Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

The cohort 1 booster phase was conducted in an observer-blind manner. Unblinded staff members, independent of the safety evaluation and other study evaluations, prepared and administered the vaccine. The Investigator or delegate in charge of safety assessment as well as the participants were blinded. The cohort 2 immunogenicity persistence and booster phase was conducted in an open-label manner. Laboratory analysts for the blood sample testing remained blinded during the whole study.

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort-1 Group 1: VRVg-2 (PrEP)/VRVg-2 (Booster)

Arm description:

A subset of adult participants who received 3 injections of VRVg-2 vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.

Arm type	Experimental
Investigational medicinal product name	VRVg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

The investigational product is VRVg and VRVg-2 was the formulation used. A dose of 0.5 mL VRVg-2 was administered as intramuscular (IM) injection into the deltoid muscle.

<b>Arm title</b>	Cohort-1 Group 2: Verorab® (PrEP)/VRVg-2 (Booster)
------------------	--

Arm description:

A subset of adult participants who received 3 injections of Verorab® vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.

Arm type	Active comparator
Investigational medicinal product name	VRVg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

The investigational product is VRVg and VRVg-2 was the formulation used. A dose of 0.5 mL VRVg-2 was administered as IM injection into the deltoid muscle.

<b>Arm title</b>	Cohort-1 Group 3: Imovax Rabies® (PrEP)/VRVg-2 (Booster)
------------------	--

**Arm description:**

A subset of adult participants who received 3 injections of Imovax Rabies® vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.

Arm type	Active comparator
Investigational medicinal product name	VRVg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The investigational product is VRVg and VRVg-2 was the formulation used. A dose of 0.5 mL VRVg-2 was administered as IM injection into the deltoid muscle.

<b>Arm title</b>	Cohort-2 Group 4: VRVg-2 (PrEP)/VRVg-2 (Booster)
------------------	--

**Arm description:**

A subset of adult participants who received VRVg-2 vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between Month 24 up to Month 36.

Arm type	Experimental
Investigational medicinal product name	VRVg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The investigational product is VRVg and VRVg-2 was the formulation used. A dose of 0.5 mL VRVg-2 was administered as IM injection into the deltoid muscle.

<b>Arm title</b>	Cohort-2 Group 5: Verorab® (PrEP)/VRVg-2 (Booster)
------------------	--

**Arm description:**

A subset of adult participants who received Verorab® vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between Month 24 up to Month 36.

Arm type	Active comparator
Investigational medicinal product name	VRVg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The investigational product is VRVg and VRVg-2 was the formulation used. A dose of 0.5 mL VRVg-2 was administered as IM injection into the deltoid muscle.

<b>Arm title</b>	Cohort-2 Group 6: Imovax Rabies® (PrEP)/VRVg-2 (Booster)
------------------	--

**Arm description:**

A subset of adult participants who received Imovax Rabies® vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between Month 24 up to Month 36.

Arm type	Active comparator
Investigational medicinal product name	VRVg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for suspension for injection
Routes of administration	Intramuscular use

**Dosage and administration details:**

The investigational product is VRVg and VRVg-2 was the formulation used. A dose of 0.5 mL VRVg-2 was



administered as IM injection into the deltoid muscle.

Number of subjects in period 2 <sup>[7]</sup>	Cohort-1 Group 1: VRVg-2 (PrEP)/VRVg-2	Cohort-1 Group 2: Verorab® (PrEP)/VRVg-2	Cohort-1 Group 3: Imovax Rabies® (PrEP)/VRVg-2 (Booster)
Started	94	31	32
SafAS	94	31	32
Completed	92	31	32
Not completed	2	0	0
Consent withdrawn by subject	2	-	-

Number of subjects in period 2 <sup>[7]</sup>	Cohort-2 Group 4: VRVg-2 (PrEP)/VRVg-2	Cohort-2 Group 5: Verorab® (PrEP)/VRVg-2	Cohort-2 Group 6: Imovax Rabies® (PrEP)/VRVg-2 (Booster)
Started	128	41	43
SafAS	128	41	43
Completed	127	41	43
Not completed	1	0	0
Consent withdrawn by subject	1	-	-

Notes:

[7] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: A subset of adult participants who received the respective vaccine in the primary series and completed the follow-up period, entered the booster phase and received booster dose of VRVg-2 vaccine at Month 12.

## Baseline characteristics

### Reporting groups

Reporting group title	Cohort-1 Group 1: VRVg-2
Reporting group description: Pediatric and adult participants received a total of 3 intramuscular (IM) injections of Purified Vero Rabies Vaccine – Serum Free (VRVg-2) in the primary series (1 injection each on Day 0, Day 7, and Day 28).	
Reporting group title	Cohort-1 Group 2: Verorab®
Reporting group description: Pediatric and adult participants received a total of 3 IM injections of Verorab® vaccine in the primary series (1 injection each on Day 0, Day 7, and Day 28).	
Reporting group title	Cohort-1 Group 3: Imovax Rabies®
Reporting group description: Pediatric and adult participants received a total of 3 IM injections of Imovax Rabies® vaccine in the primary series (1 injection each on Day 0, Day 7, and Day 28).	
Reporting group title	Cohort-2 Group 4: VRVg-2
Reporting group description: Adult participants received a total of 2 IM injections of VRVg-2 vaccine in the primary series (1 injection each on Day 0 and Day 7).	
Reporting group title	Cohort-2 Group 5: Verorab®
Reporting group description: Adult participants received a total of 2 IM injections of Verorab® vaccine in the primary series (1 injection each on Day 0 and Day 7).	
Reporting group title	Cohort-2 Group 6: Imovax Rabies®
Reporting group description: Adult participants received a total of 2 IM injections of Imovax Rabies® vaccine in the primary series (1 injection each on Day 0 and Day 7).	

Reporting group values	Cohort-1 Group 1: VRVg-2	Cohort-1 Group 2: Verorab®	Cohort-1 Group 3: Imovax Rabies®
Number of subjects	607	203	200
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	17	2	2
Children (2-11 years)	198	70	68
Adolescents (12-17 years)	90	28	30
Adults (18-64 years)	292	101	98
From 65-84 years	10	2	2
Age Continuous Units: years			
arithmetic mean	22.9	22.6	22.4
standard deviation	± 17.1	± 16.1	± 16.1
Sex: Female, Male Units: participants			
Female	399	147	122
Male	208	56	78
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	607	203	200

Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	0	0	0
Unknown or Not Reported	0	0	0

<b>Reporting group values</b>	Cohort-2 Group 4: VRVg-2	Cohort-2 Group 5: Verorab®	Cohort-2 Group 6: Imovax Rabies®
Number of subjects	420	139	139
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	416	136	139
From 65-84 years	4	3	0
Age Continuous Units: years			
arithmetic mean	37.4	38.4	37.3
standard deviation	± 11.3	± 11.1	± 10.9
Sex: Female, Male Units: participants			
Female	266	96	98
Male	154	43	41
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	420	139	139
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	0	0	0
Unknown or Not Reported	0	0	0

<b>Reporting group values</b>	Total		
Number of subjects	1708		
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)	21		
Children (2-11 years)	336		
Adolescents (12-17 years)	148		
Adults (18-64 years)	1182		
From 65-84 years	21		
Age Continuous Units: years			
arithmetic mean			
standard deviation	-		

Sex: Female, Male			
Units: participants			
Female	1128		
Male	580		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	1708		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	0		
White	0		
More than one race	0		
Unknown or Not Reported	0		

### Subject analysis sets

Subject analysis set title	Primary Series: Cohort-1 Group 1: VRVg-2
Subject analysis set type	Safety analysis
Subject analysis set description: Pediatric and adult participants who received at least one dose of VRVg-2 vaccine in the primary series Cohort 1 Group 1 (on Day 0, Day 7 or Day 28).	
Subject analysis set title	Primary Series: Cohort-1 Group 2: Verorab®
Subject analysis set type	Safety analysis
Subject analysis set description: Pediatric and adult participants who received at least one dose of Verorab® vaccine in the primary series Cohort 1 Group 2 (on Day 0, Day 7 or Day 28).	
Subject analysis set title	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Subject analysis set type	Safety analysis
Subject analysis set description: Pediatric and adult participants who received at least one dose of Imovax Rabies® vaccine in the primary series Cohort 1 Group 3 (on Day 0, Day 7 or Day 28).	
Subject analysis set title	Primary Series: Cohort-2 Group 4: VRVg-2
Subject analysis set type	Safety analysis
Subject analysis set description: Adult participants who received at least one dose of VRVg-2 vaccine in the primary series Cohort 2 Group 4 (on Day 0 or Day 7).	
Subject analysis set title	Primary Series: Cohort-2 Group 5: Verorab®
Subject analysis set type	Safety analysis
Subject analysis set description: Adult participants who received at least one dose of Verorab® vaccine in the primary series Cohort 2 Group 5 (on Day 0 or Day 7).	
Subject analysis set title	Primary Series: Cohort-2 Group 6: Imovax Rabies®
Subject analysis set type	Safety analysis
Subject analysis set description: Adult participants who received at least one dose of Imovax Rabies® vaccine in the primary series Cohort 2 Group 6 (on Day 0 or Day 7).	
Subject analysis set title	Primary Series: Cohort-1 Group 1: VRVg-2
Subject analysis set type	Per protocol
Subject analysis set description: This per-protocol analysis set (PPAS) for Day 42 included all the participants in primary series Cohort 1 Group 1 who completed the 3-dose vaccination schedule with VRVg-2 (on Day 0, Day 7 and Day 28), with no relevant protocol deviation before Day 42 (i.e., 14 days after the third vaccine).	
Subject analysis set title	Primary Series: Cohort-1 Group 2: Verorab®

Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 42 included all the participants in primary series Cohort 1 Group 2 who completed the 3-dose vaccination schedule with Verorab® (on Day 0, Day 7 and Day 28), with no relevant protocol deviation before Day 42 (i.e., 14 days after the third vaccine).	
Subject analysis set title	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 42 included all the participants in primary series Cohort 1 Group 3 who completed the 3-dose vaccination schedule with Imovax Rabies® (on Day 0, Day 7 and Day 28), with no relevant protocol deviation before Day 42 (i.e., 14 days after the third vaccine).	
Subject analysis set title	Pooled Groups 1 and 4: VRVg-2
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series, Cohort 1 Group 1 and Cohort 2 Group 4 who completed the 2-dose vaccination schedule with VRVg-2 (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Pooled Groups 2 and 5: Verorab®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series, Cohort 1 Group 2 and Cohort 2 Group 5 who completed the 2-dose vaccination schedule with Verorab® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Pooled Groups 3 and 6: Imovax Rabies®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series, Cohort 1 Group 3 and Cohort 2 Group 6 who completed the 2-dose vaccination schedule with Imovax Rabies® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Primary Series: Cohort-2 Group 4: VRVg-2
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 4 who completed the 2-dose vaccination schedule with VRVg-2 (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Primary Series: Cohort-2 Group 5: Verorab®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 5 who completed the 2-dose vaccination schedule with Verorab® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Primary Series: Cohort-2 Group 6: Imovax Rabies®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 6 who completed the 2-dose vaccination schedule with Imovax Rabies® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for booster at Month 12 included a subset of adult participants who completed the 3-dose vaccination schedule with VRVg-2 in the primary series Cohort 1 Group 1 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12, with no relevant protocol deviation before Month 12 + Day 14 (i.e., 14 days after the booster dose injection).	
Subject analysis set title	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)
Subject analysis set type	Per protocol

Subject analysis set description:

This PPAS for booster at M12 included a subset of adult participants who completed the 3-dose vaccination schedule with Verorab® in the primary series Cohort 1 Group 2 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12, with no relevant protocol deviation before Month 12 + Day 14 (i.e., 14 days after the booster dose injection).

Subject analysis set title	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies® Primed)
Subject analysis set type	Per protocol

Subject analysis set description:

This PPAS for booster at M12 included a subset of adult participants who completed the 3-dose vaccination schedule with Imovax Rabies® in the primary series Cohort 1 Group 3 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12, with no relevant protocol deviation before Month 12 + Day 14 (i.e., 14 days after the booster dose injection).

Subject analysis set title	Primary Series: Cohort-1 Group 1: VRVg-2
Subject analysis set type	Safety analysis

Subject analysis set description:

Pediatric and adult participants who received at least one dose of VRVg-2 vaccine in the primary series Cohort 1 Group 1 (on Day 0, Day 7 or Day 28).

Subject analysis set title	Primary Series: Cohort-1 Group 2: Verorab®
Subject analysis set type	Safety analysis

Subject analysis set description:

Pediatric and adult participants who received at least one dose of Verorab® vaccine in the primary series Cohort 1 Group 2 (on Day 0, Day 7 or Day 28).

Subject analysis set title	Primary Series: Cohort-2 Group 4: VRVg-2
Subject analysis set type	Safety analysis

Subject analysis set description:

Adult participants who received at least one dose of VRVg-2 vaccine in the primary series Cohort 2 Group 4 (on Day 0 or Day 7).

Subject analysis set title	Booster Phase: Cohort-1 Group 1: VRVg-2 (primed with VRVg-2)
Subject analysis set type	Safety analysis

Subject analysis set description:

This Safety Analysis Set for booster (SafASB) included a subset of adult participants who completed the 3-dose vaccination schedule with VRVg-2 in the primary series Cohort 1 Group 1 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.

Subject analysis set title	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® primed)
Subject analysis set type	Safety analysis

Subject analysis set description:

This SafASB included a subset of adult participants who completed the 3-dose vaccination schedule with Verorab® in the primary series Cohort 1 Group 2 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.

Subject analysis set title	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies® Primed)
Subject analysis set type	Safety analysis

Subject analysis set description:

This SafASB included a subset of adult participants who completed the 3-dose vaccination schedule with Imovax Rabies® in the primary series Cohort 1 Group 3 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.

Subject analysis set title	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Subject analysis set type	Per protocol

Subject analysis set description:

This PPAS for Day 28 included all the participants in primary series Cohort 1 Group 3 who completed the 2-dose vaccination schedule with Imovax Rabies® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).

Subject analysis set title	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)
Subject analysis set type	Per protocol

Subject analysis set description:

This PPAS for booster between Month 24 up to Month 36 included a subset of adult participants who completed the 2-dose vaccination schedule with VRVg-2 in the primary series Cohort 2 Group 4 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36, with no relevant protocol deviation before Month 24 + up to Month 36 + Day 14 (i.e., 14 days after the booster dose injection).

Subject analysis set title	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)
Subject analysis set type	Per protocol

Subject analysis set description:

This PPAS for booster between Month 24 up to Month 36 included a subset of adult participants who completed the 2-dose vaccination schedule with Verorab® in the primary series Cohort 2 Group 5 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36, with no relevant protocol deviation before Month 24 + up to Month 36 + Day 14 (i.e., 14 days after the booster dose injection).

Subject analysis set title	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies® Primed)
Subject analysis set type	Per protocol

Subject analysis set description:

This PPAS for booster between Month 24 up to Month 36 included a subset of adult participants who completed the 2-dose vaccination schedule with Imovax Rabies® in the primary series Cohort 2 Group 6 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36, with no relevant protocol deviation before Month 24 + up to Month 36 + Day 14 (i.e., 14 days after the booster dose injection).

Subject analysis set title	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)
Subject analysis set type	Safety analysis

Subject analysis set description:

This SafASB included a subset of adult participants who completed the 2-dose vaccination schedule with VRVg-2 in the primary series Cohort 2 Group 4 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36.

Subject analysis set title	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)
Subject analysis set type	Safety analysis

Subject analysis set description:

This SafASB included a subset of adult participants who completed the 2-dose vaccination schedule with Verorab® in the primary series Cohort 2 Group 5 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36.

Subject analysis set title	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies® Primed)
Subject analysis set type	Safety analysis

Subject analysis set description:

This SafASB included a subset of adult participants who completed the 2-dose vaccination schedule with Imovax Rabies® in the primary series Cohort 2 Group 6 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36.

Reporting group values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Number of subjects	607	203	200
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
Age Continuous Units: years arithmetic mean			

standard deviation	±	±	±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

<b>Reporting group values</b>	Primary Series: Cohort-2 Group 4: VRVg-2	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®
Number of subjects	420	139	139
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	±	±	±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

<b>Reporting group values</b>	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Number of subjects	519	169	162



Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	±	±	±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

<b>Reporting group values</b>	Pooled Groups 1 and 4: VRVg-2	Pooled Groups 2 and 5: Verorab®	Pooled Groups 3 and 6: Imovax Rabies®
Number of subjects	861	289	284
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	±	±	±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American			

White			
More than one race			
Unknown or Not Reported			

<b>Reporting group values</b>	Primary Series: Cohort-2 Group 4: VRVg-2	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®
Number of subjects	342	120	124
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	±	±	±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

<b>Reporting group values</b>	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)
Number of subjects	80	26	28
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	±	±	±

Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

Reporting group values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-2 Group 4: VRVg-2
Number of subjects	607	202	419
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years			
arithmetic mean	0	0	0
standard deviation	±	±	±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

Reporting group values	Booster Phase: Cohort-1 Group 1: VRVg-2 (primed with VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® primed)	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)
Number of subjects	94	31	32
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months)			

Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	0 ±	0 ±	0 ±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

<b>Reporting group values</b>	Primary Series: Cohort-1 Group 3: Imovax Rabies®	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)
Number of subjects	20	108	33
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	±	±	±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race			

Unknown or Not Reported			
-------------------------	--	--	--

Reporting group values	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)
Number of subjects	37	128	41
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	±	±	±
Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

Reporting group values	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)		
Number of subjects	43		
Age categorical Units: Subjects			
Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years			
Age Continuous Units: years arithmetic mean standard deviation	±		

Sex: Female, Male Units: participants			
Female Male			
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native Asian Native Hawaiian or Other Pacific Islander Black or African American White More than one race Unknown or Not Reported			

---

## End points

### End points reporting groups

Reporting group title	Cohort-1 Group 1: VRVg-2
Reporting group description: Pediatric and adult participants received a total of 3 intramuscular (IM) injections of Purified Vero Rabies Vaccine – Serum Free (VRVg-2) in the primary series (1 injection each on Day 0, Day 7, and Day 28).	
Reporting group title	Cohort-1 Group 2: Verorab®
Reporting group description: Pediatric and adult participants received a total of 3 IM injections of Verorab® vaccine in the primary series (1 injection each on Day 0, Day 7, and Day 28).	
Reporting group title	Cohort-1 Group 3: Imovax Rabies®
Reporting group description: Pediatric and adult participants received a total of 3 IM injections of Imovax Rabies® vaccine in the primary series (1 injection each on Day 0, Day 7, and Day 28).	
Reporting group title	Cohort-2 Group 4: VRVg-2
Reporting group description: Adult participants received a total of 2 IM injections of VRVg-2 vaccine in the primary series (1 injection each on Day 0 and Day 7).	
Reporting group title	Cohort-2 Group 5: Verorab®
Reporting group description: Adult participants received a total of 2 IM injections of Verorab® vaccine in the primary series (1 injection each on Day 0 and Day 7).	
Reporting group title	Cohort-2 Group 6: Imovax Rabies®
Reporting group description: Adult participants received a total of 2 IM injections of Imovax Rabies® vaccine in the primary series (1 injection each on Day 0 and Day 7).	
Reporting group title	Cohort-1 Group 1: VRVg-2 (PrEP)/VRVg-2 (Booster)
Reporting group description: A subset of adult participants who received 3 injections of VRVg-2 vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.	
Reporting group title	Cohort-1 Group 2: Verorab® (PrEP)/VRVg-2 (Booster)
Reporting group description: A subset of adult participants who received 3 injections of Verorab® vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.	
Reporting group title	Cohort-1 Group 3: Imovax Rabies® (PrEP)/VRVg-2 (Booster)
Reporting group description: A subset of adult participants who received 3 injections of Imovax Rabies® vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.	
Reporting group title	Cohort-2 Group 4: VRVg-2 (PrEP)/VRVg-2 (Booster)
Reporting group description: A subset of adult participants who received VRVg-2 vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between Month 24 up to Month 36.	
Reporting group title	Cohort-2 Group 5: Verorab® (PrEP)/VRVg-2 (Booster)
Reporting group description: A subset of adult participants who received Verorab® vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between Month 24 up to Month 36.	
Reporting group title	Cohort-2 Group 6: Imovax Rabies® (PrEP)/VRVg-2 (Booster)
Reporting group description: A subset of adult participants who received Imovax Rabies® vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between	

Subject analysis set title	Primary Series: Cohort-1 Group 1: VRVg-2
Subject analysis set type	Safety analysis
Subject analysis set description: Pediatric and adult participants who received at least one dose of VRVg-2 vaccine in the primary series Cohort 1 Group 1 (on Day 0, Day 7 or Day 28).	
Subject analysis set title	Primary Series: Cohort-1 Group 2: Verorab®
Subject analysis set type	Safety analysis
Subject analysis set description: Pediatric and adult participants who received at least one dose of Verorab® vaccine in the primary series Cohort 1 Group 2 (on Day 0, Day 7 or Day 28).	
Subject analysis set title	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Subject analysis set type	Safety analysis
Subject analysis set description: Pediatric and adult participants who received at least one dose of Imovax Rabies® vaccine in the primary series Cohort 1 Group 3 (on Day 0, Day 7 or Day 28).	
Subject analysis set title	Primary Series: Cohort-2 Group 4: VRVg-2
Subject analysis set type	Safety analysis
Subject analysis set description: Adult participants who received at least one dose of VRVg-2 vaccine in the primary series Cohort 2 Group 4 (on Day 0 or Day 7).	
Subject analysis set title	Primary Series: Cohort-2 Group 5: Verorab®
Subject analysis set type	Safety analysis
Subject analysis set description: Adult participants who received at least one dose of Verorab® vaccine in the primary series Cohort 2 Group 5 (on Day 0 or Day 7).	
Subject analysis set title	Primary Series: Cohort-2 Group 6: Imovax Rabies®
Subject analysis set type	Safety analysis
Subject analysis set description: Adult participants who received at least one dose of Imovax Rabies® vaccine in the primary series Cohort 2 Group 6 (on Day 0 or Day 7).	
Subject analysis set title	Primary Series: Cohort-1 Group 1: VRVg-2
Subject analysis set type	Per protocol
Subject analysis set description: This per-protocol analysis set (PPAS) for Day 42 included all the participants in primary series Cohort 1 Group 1 who completed the 3-dose vaccination schedule with VRVg-2 (on Day 0, Day 7 and Day 28), with no relevant protocol deviation before Day 42 (i.e., 14 days after the third vaccine).	
Subject analysis set title	Primary Series: Cohort-1 Group 2: Verorab®
Subject analysis set type	Per protocol
Subject analysis set description: This PPAS for Day 42 included all the participants in primary series Cohort 1 Group 2 who completed the 3-dose vaccination schedule with Verorab® (on Day 0, Day 7 and Day 28), with no relevant protocol deviation before Day 42 (i.e., 14 days after the third vaccine).	
Subject analysis set title	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Subject analysis set type	Per protocol
Subject analysis set description: This PPAS for Day 42 included all the participants in primary series Cohort 1 Group 3 who completed the 3-dose vaccination schedule with Imovax Rabies® (on Day 0, Day 7 and Day 28), with no relevant protocol deviation before Day 42 (i.e., 14 days after the third vaccine).	
Subject analysis set title	Pooled Groups 1 and 4: VRVg-2
Subject analysis set type	Per protocol
Subject analysis set description: This PPAS for Day 28 included all the participants in primary series, Cohort 1 Group 1 and Cohort 2 Group 4 who completed the 2-dose vaccination schedule with VRVg-2 (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	



Subject analysis set title	Pooled Groups 2 and 5: Verorab®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series, Cohort 1 Group 2 and Cohort 2 Group 5 who completed the 2-dose vaccination schedule with Verorab® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Pooled Groups 3 and 6: Imovax Rabies®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series, Cohort 1 Group 3 and Cohort 2 Group 6 who completed the 2-dose vaccination schedule with Imovax Rabies® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Primary Series: Cohort-2 Group 4: VRVg-2
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 4 who completed the 2-dose vaccination schedule with VRVg-2 (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Primary Series: Cohort-2 Group 5: Verorab®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 5 who completed the 2-dose vaccination schedule with Verorab® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Primary Series: Cohort-2 Group 6: Imovax Rabies®
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for Day 28 included all the participants in primary series Cohort 2 Group 6 who completed the 2-dose vaccination schedule with Imovax Rabies® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for booster at Month 12 included a subset of adult participants who completed the 3-dose vaccination schedule with VRVg-2 in the primary series Cohort 1 Group 1 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12, with no relevant protocol deviation before Month 12 + Day 14 (i.e., 14 days after the booster dose injection).	
Subject analysis set title	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for booster at M12 included a subset of adult participants who completed the 3-dose vaccination schedule with Verorab® in the primary series Cohort 1 Group 2 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12, with no relevant protocol deviation before Month 12 + Day 14 (i.e., 14 days after the booster dose injection).	
Subject analysis set title	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies® Primed)
Subject analysis set type	Per protocol
Subject analysis set description:	
This PPAS for booster at M12 included a subset of adult participants who completed the 3-dose vaccination schedule with Imovax Rabies® in the primary series Cohort 1 Group 3 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12, with no relevant protocol deviation before Month 12 + Day 14 (i.e., 14 days after the booster dose injection).	
Subject analysis set title	Primary Series: Cohort-1 Group 1: VRVg-2
Subject analysis set type	Safety analysis
Subject analysis set description:	
Pediatric and adult participants who received at least one dose of VRVg-2 vaccine in the primary series Cohort 1 Group 1 (on Day 0, Day 7 or Day 28).	

Subject analysis set title	Primary Series: Cohort-1 Group 2: Verorab®
Subject analysis set type	Safety analysis
Subject analysis set description: Pediatric and adult participants who received at least one dose of Verorab® vaccine in the primary series Cohort 1 Group 2 (on Day 0, Day 7 or Day 28).	
Subject analysis set title	Primary Series: Cohort-2 Group 4: VRVg-2
Subject analysis set type	Safety analysis
Subject analysis set description: Adult participants who received at least one dose of VRVg-2 vaccine in the primary series Cohort 2 Group 4 (on Day 0 or Day 7).	
Subject analysis set title	Booster Phase: Cohort-1 Group 1: VRVg-2 (primed with VRVg-2)
Subject analysis set type	Safety analysis
Subject analysis set description: This Safety Analysis Set for booster (SafASB) included a subset of adult participants who completed the 3-dose vaccination schedule with VRVg-2 in the primary series Cohort 1 Group 1 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.	
Subject analysis set title	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® primed)
Subject analysis set type	Safety analysis
Subject analysis set description: This SafASB included a subset of adult participants who completed the 3-dose vaccination schedule with Verorab® in the primary series Cohort 1 Group 2 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.	
Subject analysis set title	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies® Primed)
Subject analysis set type	Safety analysis
Subject analysis set description: This SafASB included a subset of adult participants who completed the 3-dose vaccination schedule with Imovax Rabies® in the primary series Cohort 1 Group 3 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.	
Subject analysis set title	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Subject analysis set type	Per protocol
Subject analysis set description: This PPAS for Day 28 included all the participants in primary series Cohort 1 Group 3 who completed the 2-dose vaccination schedule with Imovax Rabies® (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine).	
Subject analysis set title	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)
Subject analysis set type	Per protocol
Subject analysis set description: This PPAS for booster between Month 24 up to Month 36 included a subset of adult participants who completed the 2-dose vaccination schedule with VRVg-2 in the primary series Cohort 2 Group 4 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36, with no relevant protocol deviation before Month 24 + up to Month 36 + Day 14 (i.e., 14 days after the booster dose injection).	
Subject analysis set title	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)
Subject analysis set type	Per protocol
Subject analysis set description: This PPAS for booster between Month 24 up to Month 36 included a subset of adult participants who completed the 2-dose vaccination schedule with Verorab® in the primary series Cohort 2 Group 5 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36, with no relevant protocol deviation before Month 24 + up to Month 36 + Day 14 (i.e., 14 days after the booster dose injection).	
Subject analysis set title	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies® Primed)
Subject analysis set type	Per protocol
Subject analysis set description: This PPAS for booster between Month 24 up to Month 36 included a subset of adult participants who completed the 2-dose vaccination schedule with Imovax Rabies® in the primary series Cohort 2 Group 6	

and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36, with no relevant protocol deviation before Month 24 + up to Month 36 + Day 14 (i.e., 14 days after the booster dose injection).

Subject analysis set title	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)
Subject analysis set type	Safety analysis

Subject analysis set description:

This SafASB included a subset of adult participants who completed the 2-dose vaccination schedule with VRVg-2 in the primary series Cohort 2 Group 4 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36.

Subject analysis set title	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)
Subject analysis set type	Safety analysis

Subject analysis set description:

This SafASB included a subset of adult participants who completed the 2-dose vaccination schedule with Verorab® in the primary series Cohort 2 Group 5 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36.

Subject analysis set title	Booster Phase: Cohort-2 Group 6: VRVg-2 (Imovax Rabies® Primed)
Subject analysis set type	Safety analysis

Subject analysis set description:

This SafASB included a subset of adult participants who completed the 2-dose vaccination schedule with Imovax Rabies® in the primary series Cohort 2 Group 6 and received a booster injection of VRVg-2 vaccine in the booster phase between Month 24 up to Month 36.

### **Primary: Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to ( $\geq$ ) 0.5 IU/mL**

End point title	Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody (RVNA) Titer Greater Than or Equal to ( $\geq$ ) 0.5 IU/mL
-----------------	--

End point description:

RVNA titer against rabies virus was assessed using the Rapid Fluorescent Focus Inhibition test (RFFIT) assay method. Results are based on the per-protocol analysis set (PPAS) for Day 42 (3-dose) which included all the participants in primary series Cohort 1 Groups 1, 2 and 3 who completed their respective 3-dose vaccination schedule (on Day 0, Day 7 and Day 28), with no relevant protocol deviation before Day 42 (i.e., 14 days after the third vaccine). Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Primary
----------------	---------

End point timeframe:

Day 42 (post-vaccination)

<b>End point values</b>	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	519	169	162	
Units: percentage of participants				
number (confidence interval 95%)				
Pediatric (< 18 years): n=265, 85, 83	100 (98.6 to 100)	100 (95.8 to 100)	100 (95.7 to 100)	
Adult ( $\geq$ 18 years): n=254, 84, 79	100 (98.6 to 100)	98.8 (93.5 to 100)	100 (95.4 to 100)	

## Statistical analyses

Statistical analysis title	Statistical Analysis 1 for Primary Series Cohort 1
Statistical analysis description:	
'Primary Series: Cohort-1 Group 1: VRVg-2(pediatric)' versus (v) 'Primary Series: Cohort-1 Group 2: Verorab® (pediatric)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 688. Actual 'number of subjects included in analysis' is 350 (i.e., 265 pediatric participants in 'Primary Series: Cohort-1 Group 1: VRVg-2' and 85 pediatric participants in 'Primary Series: Cohort-1 Group 2: Verorab®').	
Comparison groups	Primary Series: Cohort-1 Group 1: VRVg-2 v Primary Series: Cohort-1 Group 2: Verorab®
Number of subjects included in analysis	688
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[1]</sup>
Parameter estimate	Percentage Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	4.3

Notes:

[1] - Non-inferiority was demonstrated if the lower limit of the 95 percent (%) confidence interval (CI) of the difference of the percentages between the test group (Group 1) and control groups (Group 2, Group 3) was greater than (>) -5% at Day 42.

Statistical analysis title	Statistical Analysis 2 for Primary Series Cohort 1
Statistical analysis description:	
'Primary Series: Cohort-1 Group 1: VRVg-2 (adult)' versus 'Primary Series: Cohort-1 Group 2: Verorab® (adult)'. The following 'number of subjects included in analysis' is being erroneously displayed as 688. Actual 'number of subjects included in analysis' is 338 (i.e., 254 adult participants in 'Primary Series: Cohort-1 Group 1: VRVg-2' and 84 adult participants in 'Primary Series: Cohort-1 Group 2: Verorab®').	
Comparison groups	Primary Series: Cohort-1 Group 1: VRVg-2 v Primary Series: Cohort-1 Group 2: Verorab®
Number of subjects included in analysis	688
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[2]</sup>
Parameter estimate	Percentage Difference
Point estimate	1.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.6
upper limit	6.4

Notes:

[2] - Non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the percentages between the test group (Group 1) and control groups (Group 2, Group 3) was > -5% at Day 42.

	Statistical Analysis 3 for Primary Series Cohort 1
--	--

Statistical analysis title	
Statistical analysis description:	
'Primary Series: Cohort-1 Group 1: VRVg-2 (pediatric)' versus 'Primary Series: Cohort-1 Group 3: Imovax Rabies® (pediatric)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 681. Actual 'number of subjects included in analysis' is 348 (i.e., 265 pediatric participants in 'Primary Series: Cohort-1 Group 1: VRVg-2' and 83 pediatric participants in 'Primary Series: Cohort-1 Group 3: Imovax Rabies®').	
Comparison groups	Primary Series: Cohort-1 Group 1: VRVg-2 v Primary Series: Cohort-1 Group 3: Imovax Rabies®
Number of subjects included in analysis	681
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[3]</sup>
Parameter estimate	Percentage Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	4.4

Notes:

[3] - Non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the percentages between the test group (Group 1) and control groups (Group 2, Group 3) was > -5% at Day 42.

Statistical analysis title	
Statistical Analysis 4 for Primary Series Cohort 1	
Statistical analysis description:	
'Primary Series: Cohort-1 Group 1: VRVg-2 (adult)' versus 'Primary Series: Cohort-1 Group 3: Imovax Rabies® (adult)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 681. Actual 'number of subjects included in analysis' is 333 (i.e., 254 adult participants in 'Primary Series: Cohort-1 Group 1: VRVg-2' and 79 adult participants in 'Primary Series: Cohort-1 Group 3: Imovax Rabies®').	
Comparison groups	Primary Series: Cohort-1 Group 1: VRVg-2 v Primary Series: Cohort-1 Group 3: Imovax Rabies®
Number of subjects included in analysis	681
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[4]</sup>
Parameter estimate	Percentage Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.5
upper limit	4.6

Notes:

[4] - Non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the percentages between the test group (Group 1) and control groups (Group 2, Group 3) was > -5% at Day 42.

## Secondary: Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL

End point title	Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL
-----------------	---

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. Results are based on the PPAS for Day 42 (3-dose) for primary series Cohort 1 Groups 1, 2 and 3. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
End point timeframe:	
Cohort 1: Day 0 (pre-vaccination), Day 28 and Day 42 (post-vaccination)	

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	519	169	162	
Units: percentage of participants				
number (confidence interval 95%)				
Day 0: n=519, 169, 162	0 (0 to 0.7)	0 (0 to 2.2)	0 (0 to 2.3)	
Day 28: n=512, 168, 160	100 (99.3 to 100)	99.4 (96.7 to 100)	98.8 (95.6 to 99.8)	
Day 42: n=519, 169, 162	100 (99.3 to 100)	99.4 (96.7 to 100)	100 (97.7 to 100)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Primary Series: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL - Pooled Population

End point title	Primary Series: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL - Pooled Population
-----------------	--

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. It was planned to collect and present pooled data of specified Groups, and separately for adults and pediatric participants in this outcome measure. Results are based on the PPAS for Day 28 (2-dose) which included all the participants in pooled 'Groups 1 and 4'; pooled 'Groups 2 and 5'; and pooled 'Groups 3 and 6' who completed their respective 2-dose vaccination schedule (on Day 0 and Day 7), with no relevant protocol deviation before Day 28 (i.e., 21 days after the second vaccine). Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
End point timeframe:	
Day 28	

End point values	Pooled Groups 1 and 4: VRVg-2	Pooled Groups 2 and 5: Verorab®	Pooled Groups 3 and 6: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	861	289	284	
Units: percentage of participants				
number (confidence interval 95%)				
Pediatric (< 18 years): n=266, 86, 81	100 (98.6 to 100)	100 (95.8 to 100)	100 (95.5 to 100)	

Adult ( $\geq 18$ years): n=595, 203, 203	98.3 (96.9 to 99.2)	98.5 (95.7 to 99.7)	96.6 (93.0 to 98.6)	
---	---------------------	---------------------	---------------------	--

## Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1 for Primary Series
-----------------------------------	---

Statistical analysis description:

'Pooled Groups 1 and 4: VRVg-2 (pediatric)' versus (v) 'Pooled Groups 2 and 5: Verorab® (pediatric)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 1150. Actual 'number of subjects included in analysis' is 352 (i.e., 266 pediatric participants in 'Pooled Groups 1 and 4: VRVg-2' and 86 pediatric participants in 'Pooled Groups 2 and 5: Verorab®').

Comparison groups	Pooled Groups 1 and 4: VRVg-2 v Pooled Groups 2 and 5: Verorab®
Number of subjects included in analysis	1150
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[5]</sup>
Parameter estimate	Percentage Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	4.3

Notes:

[5] - Non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the percentage between the test groups (Groups 1+4) and control groups (Groups 2+5, Groups 3+6) was  $> -5\%$  at Day 28.

<b>Statistical analysis title</b>	Statistical Analysis 2 for Primary Series
-----------------------------------	---

Statistical analysis description:

'Pooled Groups 1 and 4: VRVg-2 (adult)' versus 'Pooled Groups 2 and 5: Verorab® (adult)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 1150. Actual 'number of subjects included in analysis' is 798 (i.e., 595 adult participants in 'Pooled Groups 1 and 4: VRVg-2' and 203 adult participants in 'Pooled Groups 2 and 5: Verorab®').

Comparison groups	Pooled Groups 1 and 4: VRVg-2 v Pooled Groups 2 and 5: Verorab®
Number of subjects included in analysis	1150
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[6]</sup>
Parameter estimate	Percentage Difference
Point estimate	-0.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.9
upper limit	2.7

Notes:

[6] - Non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the percentage between the test groups (Groups 1+4) and control groups (Groups 2+5, Groups 3+6) was  $> -5\%$  at Day 28.

<b>Statistical analysis title</b>	Statistical Analysis 3 for Primary Series
-----------------------------------	---

#### Statistical analysis description:

'Pooled Groups 1 and 4: VRVg-2 (pediatric)' versus 'Pooled Groups 3 and 6: Imovax Rabies® (pediatric)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 1150. Actual 'number of subjects included in analysis' is 347 (i.e., 266 pediatric participants in 'Pooled Groups 1 and 4: VRVg-2' and 81 pediatric participants in 'Pooled Groups 3 and 6: Imovax Rabies®').

Comparison groups	Pooled Groups 1 and 4: VRVg-2 v Pooled Groups 3 and 6: Imovax Rabies®
Number of subjects included in analysis	1145
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[7]</sup>
Parameter estimate	Percentage Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	4.5

#### Notes:

[7] - Non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the percentage between the test groups (Groups 1+4) and control groups (Groups 2+5, Groups 3+6) was > -5% at Day 28.

<b>Statistical analysis title</b>	Statistical Analysis 4 for Primary Series
-----------------------------------	---

#### Statistical analysis description:

'Pooled Groups 1 and 4: VRVg-2 (adult)' versus 'Pooled Groups 3 and 6: Imovax Rabies® (adult)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 1150. Actual 'number of subjects included in analysis' is 798 (i.e., 595 adult participants in 'Pooled Groups 1 and 4: VRVg-2' and 203 adult participants in 'Pooled Groups 3 and 6: Imovax Rabies®').

Comparison groups	Pooled Groups 1 and 4: VRVg-2 v Pooled Groups 3 and 6: Imovax Rabies®
Number of subjects included in analysis	1145
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[8]</sup>
Parameter estimate	Percentage Difference
Point estimate	1.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5
upper limit	5.3

#### Notes:

[8] - Non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the percentage between the test groups (Groups 1+4) and control groups (Groups 2+5, Groups 3+6) was > -5% at Day 28.

### **Secondary: Primary Series: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL - Pooled Population (Groups 1 and 4) Versus Cohort 1: Group 3: Non-inferiority Analysis**

End point title	Primary Series: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL - Pooled Population (Groups 1 and 4) Versus Cohort 1: Group 3: Non-inferiority Analysis
-----------------	--

#### End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. It was planned to collect and present pooled data of specified groups, and separately for adults and pediatric participants in this outcome measure. Data for this outcome measure was planned to be collected at Day 28 for Pooled Groups 1 and 4 and at Day 42 for Primary Series: Cohort-1 Group 3: Imovax Rabies® and reported as overall data for the non-inferiority analysis in this outcome measure. Results are based on the PPAS for



Day 28 (2-dose) for 'pooled Groups 1 and 4' and the PPAS for Day 42 (3-dose) for 'primary series: Cohort 1 Group 3'. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
End point timeframe:	
Pooled Groups 1 and 4: Day 28 (post-vaccination) and Primary Series: Cohort-1 Group 3: Day 42 (post-vaccination)	

End point values	Primary Series: Cohort-1 Group 3: Imovax Rabies®	Pooled Groups 1 and 4: VRVg-2		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	162	861		
Units: percentage of participants				
number (confidence interval 95%)				
Pediatric (< 18 years): n=266, 83	100 (95.7 to 100)	100 (98.6 to 100)		
Adult (>= 18 years): n=595, 79	100 (95.4 to 100)	98.3 (96.9 to 99.2)		

## Statistical analyses

Statistical analysis title	Statistical Analysis 1 for Primary Series
Statistical analysis description:	
'Pooled Groups 1 and 4: VRVg-2 at Day 28 (pediatric)' versus (v) 'Primary Series: Cohort-1 Group 3: Imovax Rabies® at Day 42 (pediatric)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 1023. Actual 'number of subjects included in analysis' is 349 (i.e., 266 pediatric participants in 'Pooled Groups 1 and 4: VRVg-2 at Day 28' and 86 pediatric participants in 'Primary Series: Cohort-1 Group 3: Imovax Rabies® at Day 42'.	
Comparison groups	Pooled Groups 1 and 4: VRVg-2 v Primary Series: Cohort-1 Group 3: Imovax Rabies®
Number of subjects included in analysis	1023
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[9]</sup>
Parameter estimate	Percentage Difference
Point estimate	0
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.4
upper limit	4.4

Notes:

[9] - Each non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the proportions between 2-dose VRVg-2 at day (D) 28 and 3-dose Imovax Rabies® at D42 was > -10%. If the non-inferiority objective for VRVg-2 versus comparator vaccines at D28 was demonstrated, the overall non-inferiority of 2-dose VRVg-2 at D28 versus 3-dose Imovax Rabies® at D42 was demonstrated if the non-inferiority between pooled Groups 1+4 and Group 3 were both demonstrated in each age group.

Statistical analysis title	Statistical Analysis 2 for Primary Series
----------------------------	---

#### Statistical analysis description:

'Pooled Groups 1 and 4: VRVg-2 at Day 28 (adult)' versus 'Primary Series: Cohort-1 Group 3: Imovax Rabies® at Day 42 (adult)'. The following 'Number of subjects included in analysis' is being erroneously displayed as 1023. Actual 'number of subjects included in analysis' is 674 (i.e., 595 adult participants in 'Pooled Groups 1 and 4: VRVg-2 at Day 28' and 79 adult participants in 'Primary Series: Cohort-1 Group 3: Imovax Rabies® at Day 42'.

Comparison groups	Pooled Groups 1 and 4: VRVg-2 v Primary Series: Cohort-1 Group 3: Imovax Rabies®
Number of subjects included in analysis	1023
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[10]</sup>
Parameter estimate	Percentage Difference
Point estimate	-1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	-3.1
upper limit	3

#### Notes:

[10] - Each non-inferiority was demonstrated if the lower limit of the 95% CI of the difference of the proportions between 2-dose VRVg-2 at day (D) 28 and 3-dose Imovax Rabies® at D42 was > -10%. If the non-inferiority objective for VRVg-2 versus comparator vaccines at D28 was demonstrated, the overall non-inferiority of 2-dose VRVg-2 at D28 versus 3-dose Imovax Rabies® at D42 was demonstrated if the non-inferiority between pooled Groups 1+4 and Group 3 were both demonstrated in each age group.

#### **Secondary: Primary Series: Groups 1 and 4: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL - Pooled Population - Superiority Analysis**

End point title	Primary Series: Groups 1 and 4: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL - Pooled Population - Superiority Analysis
-----------------	---

#### End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. It was planned to collect and present pooled data of specified groups in this outcome measure. Results are based on the PPAS for Day 28 (2-dose) for 'pooled Groups 1 and 4'. If the non-inferiority objective of 2-dose VRVg-2 at D28 versus 3-dose Imovax Rabies® at D42 was demonstrated based on the non-inferiority (NI) margin of -10%, the superiority of VRVg-2 at D28 was demonstrated if the overall observed proportion of subjects with an RVNA titer  $\geq 0.5$  IU/mL at D28 was at least 99% in the pooled VRVg-2 Group (Groups 1+4), with the lower limit of 95% CI was at least 97%.

End point type	Secondary
----------------	-----------

#### End point timeframe:

Day 28 (post-vaccination)

<b>End point values</b>	Pooled Groups 1 and 4: VRVg-2			
Subject group type	Subject analysis set			
Number of subjects analysed	861			
Units: percentage of participants				
number (confidence interval 95%)	98.8 (97.9 to 99.4)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Primary Series Cohort 1 Group 3: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL - Non-Inferiority Analysis

End point title	Primary Series Cohort 1 Group 3: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL - Non-Inferiority Analysis
-----------------	--

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. Results are based on the PPAS for Day 28 (2-dose) and the PPAS for Day 42 (3-dose) for 'primary series: Cohort-1 Group 3'. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 28 and Day 42 (post-vaccination)

<b>End point values</b>	Primary Series: Cohort-1 Group 3: Imovax Rabies®			
Subject group type	Subject analysis set			
Number of subjects analysed	162			
Units: percentage of participants				
number (confidence interval 95%)				
Day 28: n=160	98.8 (95.6 to 99.8)			
Day 42: n=162	100 (97.7 to 100)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Primary Series Cohort 1: Rabies Virus Neutralizing Antibody Geometric Mean Titers (GMTs) Against Rabies Virus

End point title	Primary Series Cohort 1: Rabies Virus Neutralizing Antibody Geometric Mean Titers (GMTs) Against Rabies Virus
-----------------	---

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. Results are based on the PPAS for Day 42 (3-dose) for primary series Cohort 1 Groups 1, 2 and 3. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 0 (pre-vaccination), Day 28 and Day 42 (post-vaccination)

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	519	169	162	
Units: IU/mL				
geometric mean (confidence interval 95%)				
Day 0: n=519, 169, 162	0.100 (0.100 to 0.100)	0.101 (0.100 to 0.102)	0.101 (0.100 to 0.101)	
Day 28: n=512, 168, 160	7.16 (6.66 to 7.69)	4.90 (4.31 to 5.57)	5.13 (4.48 to 5.87)	
Day 42: n=519, 169, 162	24.0 (22.4 to 25.7)	20.0 (17.6 to 22.8)	16.4 (14.7 to 18.3)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Primary Series Cohort 2: Rabies Virus Neutralizing Antibody Geometric Mean Titers (GMTs) Against Rabies Virus

End point title	Primary Series Cohort 2: Rabies Virus Neutralizing Antibody Geometric Mean Titers (GMTs) Against Rabies Virus
-----------------	---

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. Results are based on the PPAS for Day 28 (2-dose) for primary series Cohort 2 Groups 4, 5 and 6. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 2: Day 0 (pre-vaccination) and Day 28 (post-vaccination)

End point values	Primary Series: Cohort-2 Group 4: VRVg-2	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	342	120	124	
Units: IU/mL				
geometric mean (confidence interval 95%)				
Day 0: n=342, 120, 124	0.101 (0.100 to 0.101)	0.101 (0.100 to 0.101)	0.100 (0.100 to 0.101)	
Day 28: n=342, 120, 124	3.79 (3.42 to 4.20)	2.92 (2.45 to 3.48)	3.91 (3.25 to 4.70)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Primary Series Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL

End point title	Primary Series Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL
End point description: RVNA titer against rabies virus was assessed using the RFFIT assay method. Results are based on the PPAS for Day 28 (2-dose) for primary series Cohort 2 Groups 4, 5 and 6. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.	
End point type	Secondary
End point timeframe: Cohort 2: Day 0 (pre-vaccination) and Day 28 (post-vaccination)	

End point values	Primary Series: Cohort-2 Group 4: VRVg-2	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	342	120	124	
Units: percentage of participants				
number (confidence interval 95%)				
Day 0: n=342, 120, 124	0 (0.0 to 1.1)	0 (0.0 to 3.0)	0 (0.0 to 2.9)	
Day 28: n=342, 120, 124	97.1 (94.7 to 98.6)	98.3 (94.1 to 99.8)	96.0 (90.8 to 98.7)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.2$ IU/mL (Lower Limit of Quantification [LLOQ])

End point title	Primary Series Cohort 1: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.2$ IU/mL (Lower Limit of Quantification [LLOQ])
End point description: RVNA titer against rabies virus was assessed using the RFFIT assay method. LLOQ for the RFFIT assay was 0.2 IU/mL. Results are based on the PPAS for Day 42 (3-dose) for primary series Cohort 1 Groups 1, 2 and 3. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.	
End point type	Secondary
End point timeframe: Cohort 1: Day 0 (pre-vaccination), Day 28 and Day 42 (post-vaccination)	

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	519	169	162	
Units: percentage of participants				
number (confidence interval 95%)				
Day 0: n=519, 169, 162	0 (0 to 0.7)	0 (0 to 2.2)	0 (0 to 2.3)	
Day 28: n=512, 168, 160	100 (99.3 to 100)	99.4 (96.7 to 100)	100 (97.7 to 100)	
Day 42: n=519, 169, 162	100 (99.3 to 100)	99.4 (96.7 to 100)	100 (97.7 to 100)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Primary Series Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.2$ IU/mL (Lower Limit of Quantification [LLOQ])

End point title	Primary Series Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.2$ IU/mL (Lower Limit of Quantification [LLOQ])
-----------------	--

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. LLOQ for the RFFIT assay was 0.2 IU/mL. Results are based on the PPAS for Day 28 (2-dose) for primary series Cohort 2 Groups 4, 5 and 6. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 2: Day 0 (pre-vaccination) and Day 28 (post-vaccination)

End point values	Primary Series: Cohort-2 Group 4: VRVg-2	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	342	120	124	
Units: percentage of participants				
number (confidence interval 95%)				
Day 0: n=342, 120, 124	0 (0 to 1.1)	0 (0 to 3.0)	0 (0 to 2.9)	
Day 28: n=342, 120, 124	99.7 (98.4 to 100)	100 (97.0 to 100)	98.4 (94.3 to 99.8)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Primary Series Cohort 1: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers

End point title	Primary Series Cohort 1: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers
-----------------	---

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs post-vaccination (i.e., on Day 28 and Day 42) and pre-vaccination on Day 0. Results are based on the PPAS for Day 42 (3-dose) for primary series Cohort 1 Groups 1, 2 and 3. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 0 (pre-vaccination), Day 28 and Day 42 (post-vaccination)

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	519	169	162	
Units: ratio				
geometric mean (confidence interval 95%)				
Day 28/Day 0: n=512, 168, 160	71.5 (66.6 to 76.8)	48.7 (42.8 to 55.3)	51.0 (44.6 to 58.3)	
Day 42/Day 0: n=519, 169, 162	240 (224 to 256)	199 (174 to 226)	163 (146 to 182)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Primary Series Cohort 2: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers

End point title	Primary Series Cohort 2: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers
-----------------	---

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs post-vaccination (i.e., on Day 28) and pre-vaccination on Day 0. Results are based on the PPAS for Day 28 (2-dose) for primary series Cohort 2 Groups 4, 5 and 6.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 2: Day 0 (pre-vaccination) and Day 28 (post-vaccination)

End point values	Primary Series: Cohort-2 Group 4: VRVg-2	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	342	120	124	
Units: ratio				
geometric mean (confidence interval 95%)	37.7 (34.0 to 41.8)	29.0 (24.4 to 34.6)	38.9 (32.4 to 46.7)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Primary Series Cohort 1: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization

End point title	Primary Series Cohort 1: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization
-----------------	---

End point description:

Virus neutralization was defined as complete (absence of fluorescent cells) and incomplete (presence of fluorescent cells) at the participant/timepoint level at the starting dilution (1/5) of RFFIT assay. Percentage of participants with determined complete and determined incomplete virus neutralization were reported. Results are based on the PPAS for Day 42 (3-dose) for primary series Cohort 1 Groups 1, 2 and 3. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Cohort 1: Day 0 (pre-vaccination), Day 28 and Day 42 (post-vaccination)

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	519	169	162	
Units: percentage of participants				
number (confidence interval 95%)				
Day 0 - Complete neutralization: n=504, 166, 158	0.2 (0 to 1.1)	0.6 (0 to 3.3)	1.3 (0.2 to 4.5)	
Day 0 - Incomplete neutralization: n=504, 166, 158	99.8 (98.9 to 100)	99.4 (96.7 to 100)	98.7 (95.5 to 99.8)	
Day 28, Complete neutralization: n=514, 167, 161	100 (99.3 to 100)	99.4 (96.7 to 100)	99.4 (96.6 to 100)	
Day 28, Incomplete neutralization: n=514, 167, 161	0 (0 to 0.7)	0.6 (0 to 3.3)	0.6 (0 to 3.4)	
Day 42, Complete neutralization: n=518, 169, 161	100 (99.3 to 100)	99.4 (96.7 to 100)	100 (97.7 to 100)	
Day 42, Incomplete neutralization: n=518, 169, 161	0 (0 to 0.7)	0.6 (0 to 3.3)	0 (0 to 2.3)	



## Statistical analyses

No statistical analyses for this end point

### Secondary: Primary Series Cohort 2: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization

End point title	Primary Series Cohort 2: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization
End point description: Virus neutralization was defined as complete (absence of fluorescent cells) and incomplete (presence of fluorescent cells) at the participant/timepoint level at the starting dilution (1/5) of RFFIT assay. Percentage of participants with determined complete and determined incomplete virus neutralization were reported. Results are based on the PPAS for Day 28 (2-dose) for primary series Cohort 2 Groups 4, 5 and 6. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.	
End point type	Secondary
End point timeframe: Cohort 2: Day 0 (pre-vaccination) and Day 28 (post-vaccination)	

End point values	Primary Series: Cohort-2 Group 4: VRVg-2	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	342	120	124	
Units: percentage of participants				
number (confidence interval 95%)				
Day 0, Complete neutralization: n=330, 119, 117	0.9 (0.2 to 2.6)	4.2 (1.4 to 9.5)	0 (0 to 3.1)	
Day 0, Incomplete neutralization: n=330, 119, 117	99.1 (97.4 to 99.8)	95.8 (90.5 to 98.6)	100 (96.9 to 100)	
Day 28, Complete neutralization: n=339, 120, 124	100 (98.9 to 100)	100 (97.0 to 100)	98.4 (94.3 to 99.8)	
Day 28, Incomplete neutralization: n=339, 120, 124	0 (0 to 1.1)	0 (0 to 3.0)	1.6 (0.2 to 5.7)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Phase: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus

End point title	Booster Phase: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus
-----------------	--

**End point description:**

RVNA titer against rabies virus was assessed using the RFFIT assay method. Results are based on the PPAS for booster at Month 12 which included adult participants who received 3 injections of corresponding study vaccine in the primary series Cohort 1 and received a booster injection of VRVg-2 vaccine in the booster phase at Month 12, with no relevant protocol deviation before Month 12 + Day 14 (i.e., 14 days after the booster dose injection). Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Month 12 (pre-booster dose) and Month 12 + Day 14 (post-booster dose)

<b>End point values</b>	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	80	26	28	
Units: IU/mL				
geometric mean (confidence interval 95%)				
Month 12: n=80, 26, 28	0.679 (0.526 to 0.878)	0.540 (0.344 to 0.848)	0.487 (0.311 to 0.764)	
Month 12 + 14 Days: n=80, 26, 28	56.5 (45.4 to 70.3)	57.1 (42.6 to 76.7)	33.7 (22.6 to 50.3)	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Booster Phase: Percentage of Participants With Rabies Virus  
Neutralizing Antibody Titers  $\geq 0.5$  IU/mL**

End point title	Booster Phase: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL
-----------------	--

**End point description:**

RVNA titer against rabies virus was assessed using the RFFIT assay method. Results are based on the PPAS for booster at Month 12. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Month 12 (pre-booster dose) and Month 12 + Day 14 (post-booster dose)

End point values	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	80	26	28	
Units: percentage of participants				
number (confidence interval 95%)				
Month 12: n=80, 26, 28	53.8 (42.2 to 65.0)	53.8 (33.4 to 73.4)	35.7 (18.6 to 55.9)	
Month 12 + 14 days: n=80, 26, 28	100 (95.5 to 100)	100 (86.8 to 100)	100 (87.7 to 100)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Phase: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.2$ IU/mL (LLOQ)

End point title	Booster Phase: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.2$ IU/mL (LLOQ)
End point description:	
RVNA titer against rabies virus was assessed using the RFFIT assay method. LLOQ for the RFFIT assay was 0.2 IU/ mL. Results are based on the PPAS for booster at Month 12. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.	
End point type	Secondary
End point timeframe:	
Month 12 (pre-booster dose) and Month 12 + Day 14 (post-booster dose)	

End point values	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	80	26	28	
Units: percentage of participants				
number (confidence interval 95%)				
Month 12: n=80, 26, 28	86.3 (76.7 to 92.9)	76.9 (56.4 to 91.0)	85.7 (67.3 to 96.0)	
Month 12 + 14 days: n=80, 26, 28	100 (95.5 to 100)	100 (86.8 to 100)	100 (87.7 to 100)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Phase: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers

End point title	Booster Phase: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers
-----------------	---

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs post vaccination (i.e., on Month 12 and Month 12 + Day 14) and pre-vaccination on Day 0, pre-booster dose on Month 12. Results are based on the PPAS for booster at Month 12. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 0 (pre-vaccination), Month 12 (pre-booster dose) and Month 12 + Day 14 (post-booster dose)

End point values	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	80	26	28	
Units: ratio				
geometric mean (confidence interval 95%)				
Month 12/Day 0: n=80, 26, 28	6.79 (5.26 to 8.78)	5.40 (3.44 to 8.48)	4.78 (3.10 to 7.37)	
Month 12+14 days/Day 0: n=80, 26, 28	565 (454 to 703)	571 (426 to 767)	331 (219 to 500)	
Month 12+14 days/Month 12: n=80, 26, 28	83.2 (62.0 to 112)	106 (62.7 to 178)	69.2 (39.6 to 121)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Phase: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization

End point title	Booster Phase: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization
-----------------	---

End point description:

Virus neutralization was defined as complete (absence of fluorescent cells) and incomplete (presence of fluorescent cells) at the participant/timepoint level at the starting dilution (1/5) of RFFIT assay. Percentage of participants with determined complete and determined incomplete virus neutralization were reported. Results are based on the PPAS for booster at Month 12. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 12 (pre-booster dose) and Month (M) 12 + Day (D) 14 (post-booster dose)

End point values	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	80	26	28	
Units: percentage of participants				
number (confidence interval 95%)				
M12: - Complete neutralization: n=80, 26, 28	96.1 (89.0 to 99.2)	84.0 (63.9 to 95.5)	95.7 (78.1 to 99.9)	
M12 - Incomplete neutralization: n=80, 26, 28	3.9 (0.8 to 11.0)	16.0 (4.5 to 36.1)	4.3 (0.1 to 21.9)	
M12 + D14 - Complete neutralization: n=80, 26, 28	100 (95.5 to 100)	100 (86.8 to 100)	100 (87.2 to 100)	
M12 + D14- Incomplete neutralization: n=80, 26, 28	0 (0 to 4.5)	0 (0 to 13.2)	0 (0 to 12.8)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Phase Cohort 2: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus

End point title	Booster Phase Cohort 2: Rabies Virus Neutralizing Antibody (RVNA) Geometric Mean Titers (GMTs) Against Rabies Virus
End point description:	
RVNA titer against rabies virus was assessed using the RFFIT assay method. Results are based on the PPAS for booster between Month 24 up to Month 36 that included a subset of adults who received a 1 week 2-dose regimen and a single booster dose of VRVg-2 between Month 24 and up to Month 36 after the first vaccination of the primary series with no relevant protocol deviation before Month 24 up to Month 36 + Day 14.	
End point type	Secondary
End point timeframe:	
Month 24 up to Month 36 (pre-booster dose) and Month 24 up to Month 36 + Day 14 (post-booster dose)	

End point values	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	108	33	37	
Units: IU/mL				
geometric mean (confidence interval 95%)				

Month 24 up to Month 36	0.761 (0.607 to 0.953)	0.536 (0.385 to 0.747)	0.903 (0.603 to 1.35)	
Month 24 up to Month 36 + 14 Days	95.4 (76.7 to 119)	89.4 (55.8 to 143)	64.7 (43.7 to 95.9)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Phase Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL

End point title	Booster Phase Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.5$ IU/mL
-----------------	--

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. Percentages are rounded off to the tenth decimal place. Results are based on the PPAS for booster between Month 24 up to Month 36.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 24 up to Month 36 (pre-booster dose) and Month 24 up to Month 36 + Day 14 (post-booster dose)

End point values	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	108	33	37	
Units: percentage of participants				
number (confidence interval 95%)				
Month 24 up to Month 36	62.0 (52.2 to 71.2)	51.5 (33.5 to 69.2)	64.9 (47.5 to 79.8)	
Month 24 up to Month 36 + 14 Days	100 (96.6 to 100)	100 (89.4 to 100)	100 (90.5 to 100)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Phase Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.2$ IU/mL (lower limit of quantification [LLOQ])

End point title	Booster Phase Cohort 2: Percentage of Participants With Rabies Virus Neutralizing Antibody Titers $\geq 0.2$ IU/mL (lower limit of quantification [LLOQ])
-----------------	---

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. LLOQ for the RFFIT assay was 0.2 IU/mL. Percentages are rounded off to the tenth decimal place. Results are based on the PPAS

for booster between Month 24 up to Month 36.

End point type	Secondary
End point timeframe:	
Month 24 up to Month 36 (pre-booster dose) and Month 24 up to Month 36 + Day 14 (post-booster dose)	

End point values	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	108	33	37	
Units: percentage of participants				
number (confidence interval 95%)				
Month 24 up to Month 36	89.8 (82.5 to 94.8)	87.9 (71.8 to 96.6)	89.2 (74.6 to 97.0)	
Month 24 up to Month 36 + 14 Days	100 (96.6 to 100)	100 (89.4 to 100)	100 (90.5 to 100)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Booster Phase Cohort 2: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers

End point title	Booster Phase Cohort 2: Geometric Mean Titer Ratio (GMTR) of Rabies Virus Neutralizing Antibody Titers
-----------------	--

End point description:

RVNA titer against rabies virus was assessed using the RFFIT assay method. GMTRs were calculated as the ratio of GMTs pre-booster/pre-vaccination (Month 24 up to Month 36/Day 0); post-booster/pre-vaccination (Month 24 up to Month 36 +14 days/Day 0); post-booster/pre-booster (Month 24 up to Month 36+14 days/Month 24 up to Month 36). Results are based on the PPAS for booster between Month 24 up to Month 36.

End point type	Secondary
End point timeframe:	
Day 0 (pre-vaccination), Month 24 up to Month 36 (pre-booster dose) and Month 24 up to Month 36 + Day 14 (post-booster dose)	

End point values	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	108	33	37	
Units: ratio				

geometric mean (confidence interval 95%)				
Month 24 up to Month 36/Day 0	7.58 (6.06 to 9.48)	5.30 (3.80 to 7.40)	9.03 (6.03 to 13.5)	
Month 24 up to Month 36 +14 days/Day 0	951 (764 to 1184)	885 (548 to 1430)	647 (437 to 959)	
Month24 upto Month36+14 days/Month24 upto Month36	125 (98.1 to 160)	167 (101 to 276)	71.7 (42.3 to 122)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Booster Phase Cohort 2: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization

End point title	Booster Phase Cohort 2: Percentage of Participants With Determined Complete and Determined Incomplete Virus Neutralization
-----------------	--

End point description:

Virus neutralization was defined as complete (absence of fluorescent cells) and incomplete (presence of fluorescent cells) at the participant/timepoint level at the starting dilution (1/5) of RFFIT assay. Percentage of participants with determined complete and determined incomplete virus neutralization were reported. Percentages are rounded off to the tenth decimal place. Results are based on the PPAS for Booster between Month 24 up to Month 36. Here, 'number of subjects analyzed' = number of participants with available data for this outcome measure and 'n' = number of participants with available data for each specified category. Complete neutralization: CN and incomplete neutralization: IN.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 24 up to Month 36 (pre-booster dose) and Month 24 up to Month 36 + Day 14 (post-booster dose)

End point values	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	108	33	37	
Units: percentage of participants				
number (confidence interval 95%)				
Month 24 up to Month 36 - CN: n=107, 33, 37	94.1 (87.5 to 97.8)	93.8 (79.2 to 99.2)	91.9 (78.1 to 98.3)	
Month 24 up to Month 36 - IN: n=107, 33, 37	5.9 (2.2 to 12.5)	6.3 (0.8 to 20.8)	8.1 (1.7 to 21.9)	
Month 24 up to Month 36+14 days- CN:n=108, 33, 37	100 (96.6 to 100)	100 (89.4 to 100)	100 (90.5 to 100)	
Month 24 up to Month 36+14 days- IN:n=108, 33, 37	0 (0 to 3.4)	0 (0 to 10.6)	0 (0 to 9.5)	



## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Immediate Unsolicited Adverse Events (AEs)

End point title	Number of Participants With Immediate Unsolicited Adverse Events (AEs)
End point description:	
An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessarily had to have a causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset post-vaccination. All participants were observed for 30 minutes after any vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRB. Results are based on the safety analysis set (SafAS) that included participants who had received at least one dose of the study vaccine and were analyzed according to the actual treatment received.	
End point type	Secondary
End point timeframe:	
Within 30 minutes after any vaccination	

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	Primary Series: Cohort-2 Group 4: VRVg-2
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	607	202	200	419
Units: participants	0	0	0	0

End point values	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	Booster Phase: Cohort-1 Group 1: VRVg-2 (primed with VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® primed)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	139	139	94	31
Units: participants	0	0	0	0

End point values	Booster Phase: Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	128	41	43
Units: participants	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Solicited Systemic Reactions

End point title	Number of Participants With Solicited Systemic Reactions
End point description:	
A solicited systemic reaction (SR) was an expected AR observed and reported under conditions (nature & onset) pre-listed in the protocol and CRB and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited systemic reactions included fever (F), vomiting, crying abnormal, drowsiness, appetite loss, irritability, headache (H), malaise (M) and myalgia (MG). Solicited systemic reactions were collected by different age groups: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability were collected for participants aged 12 to 23 months. Fever, Headache, Malaise and Myalgia were collected for participants aged $\geq 2$ years. Results are based on the SafAS. Here, n= number of participants with available data for each specified category; 9999= no participants were analyzed for the particular category.	
End point type	Secondary
End point timeframe:	
Within 7 Days after any vaccination.	

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	Primary Series: Cohort-2 Group 4: VRVg-2
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	607	202	200	419
Units: participants				
F: n=606,201,200,419,139,139,94,31,32,128,41,43	50	11	4	2
Vomiting: n=17,2,2,0,0,0,0,0,0,0,0	4	1	1	9999
Crying abnormal: n=17,2,2,0,0,0,0,0,0,0,0	8	0	1	9999
Drowsiness: n=17,2,2,0,0,0,0,0,0,0,0	4	1	0	9999
Appetite lost: n=17,2,2,0,0,0,0,0,0,0,0	3	1	0	9999
Irritability: n=17,2,2,0,0,0,0,0,0,0,0	8	1	0	9999
H: n=590,199,198,419,139,139,94,31,32,128,41,43	128	49	46	39
M:n=590,199,198,419,139,139,94,31,32,128,41,43	161	45	48	37
MG:n=590,199,198,419,139,139,94,31,32,128,41,43	249	66	78	78

<b>End point values</b>	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	Booster Phase: Cohort-1 Group 1: VRVg-2 (primed with VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® primed)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	139	139	94	31
Units: participants				
F: n=606,201,200,419,139,139,94,31,32, 128,41,43	0	0	0	0
Vomiting: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
Crying abnormal: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
Drowsiness: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
Appetite lost: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
Irritability: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
H: n=590,199,198,419,139,139,94,31,32, 128,41,43	9	8	4	3
M:n=590,199,198,419,139,139,94,31,3 2,128,41,43	10	12	8	3
MG:n=590,199,198,419,139,139,94,31, 32,128,41,43	12	29	23	9

<b>End point values</b>	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	128	41	43
Units: participants				
F: n=606,201,200,419,139,139,94,31,32, 128,41,43	0	0	0	0
Vomiting: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
Crying abnormal: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
Drowsiness: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
Appetite lost: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
Irritability: n=17,2,2,0,0,0,0,0,0,0,0	9999	9999	9999	9999
H: n=590,199,198,419,139,139,94,31,32, 128,41,43	5	3	0	0
M:n=590,199,198,419,139,139,94,31,3 2,128,41,43	7	5	1	0

MG:n=590,199,198,419,139,139,94,31, 32,128,41,43	15	10	0	0
---	----	----	---	---

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Solicited Injection Site Reactions

End point title	Number of Participants With Solicited Injection Site Reactions
-----------------	--

End point description:

A solicited reaction (SR) was an expected AR observed and reported under conditions (nature and onset) pre-listed (i.e., solicited) in the protocol and CRB and considered as related to vaccination. An AR was all noxious and unintended responses to a medicinal product related to any dose. Solicited injection site reactions included tenderness/pain, erythema and swelling. Results are based on the SafAS.

End point type	Secondary
----------------	-----------

End point timeframe:

Within 7 Days after any vaccination

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	Primary Series: Cohort-2 Group 4: VRVg-2
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	607	202	200	419
Units: participants				
Injection site tenderness/pain	344	95	106	111
Injection site erythema	24	6	6	0
Injection site swelling	14	4	13	1

End point values	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	Booster Phase: Cohort-1 Group 1: VRVg-2 (primed with VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® primed)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	139	139	94	31
Units: participants				
Injection site tenderness/pain	30	43	44	12
Injection site erythema	0	1	0	0
Injection site swelling	0	1	0	1

End point values	Booster Phase:Cohort-1	Booster Phase: Cohort-2 Group	Booster Phase: Cohort-2 Group	Booster Phase:Cohort-2
------------------	---------------------------	----------------------------------	----------------------------------	---------------------------

	3: VRVg-2 (Imovax Rabies® Primed)	4: VRVg-2 (Primed With VRVg-2)	5: VRVg-2 (Verorab® Primed)	6: VRVg-2 (Imovax Rabies® Primed)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	128	41	43
Units: participants				
Injection site tenderness/pain	17	20	2	6
Injection site erythema	0	0	0	0
Injection site swelling	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Unsolicited Adverse Events

End point title	Number of Participants With Unsolicited Adverse Events
End point description:	
An AE was defined as any untoward medical occurrence in a participant who received study vaccine and does not necessarily had to have a causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions pre-listed in the CRB in terms of diagnosis and/or onset post-vaccination. Results are based on the SafAS.	
End point type	Secondary
End point timeframe:	
Within 28 Days after any vaccination	

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	Primary Series: Cohort-2 Group 4: VRVg-2
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	607	202	200	419
Units: participants	137	45	40	44

End point values	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	Booster Phase: Cohort-1 Group 1: VRVg-2 (primed with VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® primed)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	139	139	94	31
Units: participants	18	12	13	3

End point values	Booster Phase:Cohort-1	Booster Phase: Cohort-2 Group	Booster Phase: Cohort-2 Group	Booster Phase:Cohort-2
------------------	---------------------------	----------------------------------	----------------------------------	---------------------------

	3: VRVg-2 (Imovax Rabies® Primed)	4: VRVg-2 (Primed With VRVg-2)	5: VRVg-2 (Verorab® Primed)	6: VRVg-2 (Imovax Rabies® Primed)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	128	41	43
Units: participants	5	15	1	3

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

End point title	Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
-----------------	--

End point description:

An SAEs was any untoward medical occurrence that at any dose resulted in death, life-threatening, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or a medically important event. An AESI was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. All SAEs and AESIs occurring during the study that were related to the product administered were reported by the Investigator to the Independent Ethics Committee/Institutional Review Board. Relatedness to study vaccine was based on Investigator's discretion. Results are based on the SafAS. The Booster Phase for Cohort-2 has not yet started, and data for that phase will be reported at time of final results posting.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline (Day 0) up to 6 months after last vaccination (i.e., up to 7 months for Primary Series Cohorts 1 & 2 and up to Month 18 for Booster Phase Cohort 1, and up to Month 42 for Booster Phase Cohort 2)

End point values	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 3: Imovax Rabies®	Primary Series: Cohort-2 Group 4: VRVg-2
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	607	202	20	419
Units: participants				
SAEs	10	3	5	0
AESIs	0	0	0	0

End point values	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 6: Imovax Rabies®	Booster Phase: Cohort-1 Group 1: VRVg-2 (primed with VRVg-2)	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® primed)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	139	139	94	31
Units: participants				

SAEs	0	0	2	0
AESIs	0	0	0	0

<b>End point values</b>	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	32	128	41	43
Units: participants				
SAEs	1	3	0	1
AESIs	0	0	0	0

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Baseline (Day 0) up to 6 months after last vaccination (i.e., up to 7 months for Primary Series Cohorts 1 & 2 and up to Month 18 for Booster Phase Cohort 1, and up to Month 42 for Booster Phase Cohort 2).

Adverse event reporting additional description:

Unsolicited AE: from D0 up to D28 post any vaccination. SR data: within 7 days post any vaccination. AE data are based on the SafAS. In the AE section, solicited reaction (SR), fever is reported as pyrexia.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

### Reporting groups

Reporting group title	Primary Series: Cohort-1 Group 2: Verorab®
-----------------------	--

Reporting group description:

Pediatric and adult participants received a total of 3 IM injections of Verorab® vaccine in the primary series (1 injection each on Day 0, Day 7, and Day 28).

Reporting group title	Primary Series: Cohort-1 Group 1: VRVg-2
-----------------------	--

Reporting group description:

Pediatric and adult participants received a total of 3 IM injections of VRVg-2 in the primary series (1 injection each on Day 0, Day 7, and Day 28).

Reporting group title	Primary Series: Cohort-1 Group 3: Imovax Rabies®
-----------------------	--

Reporting group description:

Pediatric and adult participants received a total of 3 IM injections of Imovax Rabies® vaccine in the primary series (1 injection each on Day 0, Day 7, and Day 28).

Reporting group title	Primary Series: Cohort-2 Group 5: Verorab®
-----------------------	--

Reporting group description:

Adult participants received a total of 2 IM injections of Verorab® vaccine in the primary series (1 injection each on Day 0 and Day 7).

Reporting group title	Primary Series: Cohort-2 Group 4: VRVg-2
-----------------------	--

Reporting group description:

Adult participants received a total of 2 IM injections of VRVg-2 vaccine in the primary series (1 injection each on Day 0 and Day 7).

Reporting group title	Primary Series: Cohort-2 Group 6: Imovax Rabies®
-----------------------	--

Reporting group description:

Adult participants received a total of 2 IM injections of Imovax Rabies® vaccine in the primary series (1 injection each on Day 0 and Day 7).

Reporting group title	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)
-----------------------	---

Reporting group description:

A subset of adult participants who received 3 injections of Verorab® vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.

Reporting group title	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)
-----------------------	--

Reporting group description:

A subset of adult participants who received 3 injections of VRVg-2 vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase at Month 12.

Reporting group title	Booster Phase: Cohort-1 Group 3: VRVg-2 (Imovax Rabies® Primed)
-----------------------	---

Reporting group description:

A subset of adult participants who received 3 injections of Imovax Rabies® vaccine in the primary series and completed the follow-up period received a booster injection of VRVg-2 vaccine in the booster phase



at Month 12.

Reporting group title	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)
-----------------------	---

Reporting group description:

A subset of adult participants who received Verorab® vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between Month 24 up to Month 36.

Reporting group title	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)
-----------------------	--

Reporting group description:

A subset of adult participants who received VRVg-2 vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between Month 24 up to Month 36.

Reporting group title	Booster Phase: Cohort-2 Group 6: VRVg-2 (Imovax Rabies® Primed)
-----------------------	---

Reporting group description:

A subset of adult participants who received Imovax Rabies® vaccination in primary series and completed the follow-up period received a booster injection of VRVg-2 in the booster phase between Month 24 up to Month 36.

<b>Serious adverse events</b>	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 202 (1.49%)	10 / 607 (1.65%)	5 / 200 (2.50%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma Of The Cervix			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine Leiomyoma			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Exposure To Communicable Disease			
subjects affected / exposed	0 / 202 (0.00%)	4 / 607 (0.66%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional Overdose			

subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	1 / 200 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratorhexis			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	1 / 200 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament Injury			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	1 / 200 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple Fractures			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road Traffic Accident			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Hemiplegia			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Ectopic Pregnancy			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Imminent Abortion			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	1 / 200 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Food Allergy			
subjects affected / exposed	1 / 202 (0.50%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	1 / 202 (0.50%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Uterine Polyp			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic Obstructive Pulmonary Disease			
subjects affected / exposed	0 / 202 (0.00%)	1 / 607 (0.16%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 202 (0.00%)	1 / 607 (0.16%)	1 / 200 (0.50%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Dengue Fever			
subjects affected / exposed	0 / 202 (0.00%)	1 / 607 (0.16%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup Infectious			
subjects affected / exposed	0 / 202 (0.00%)	1 / 607 (0.16%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 202 (0.00%)	1 / 607 (0.16%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious Mononucleosis			
subjects affected / exposed	0 / 202 (0.00%)	1 / 607 (0.16%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus Infection			
subjects affected / exposed	1 / 202 (0.50%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Wound Infection			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic Shock			
subjects affected / exposed	0 / 202 (0.00%)	0 / 607 (0.00%)	0 / 200 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Primary Series:	Primary Series:	Primary Series:
-------------------------------	-----------------	-----------------	-----------------

	Cohort-2 Group 5: Verorab®	Cohort-2 Group 4: VRVg-2	Cohort-2 Group 6: Imovax Rabies®
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 139 (0.00%)	2 / 419 (0.48%)	1 / 139 (0.72%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma Of The Cervix			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine Leiomyoma			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	1 / 139 (0.72%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Exposure To Communicable Disease			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional Overdose			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratorhexis			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament Injury			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple Fractures			

subjects affected / exposed	0 / 139 (0.00%)	1 / 419 (0.24%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road Traffic Accident			
subjects affected / exposed	0 / 139 (0.00%)	1 / 419 (0.24%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Hemiplegia			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Ectopic Pregnancy			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Imminent Abortion			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Food Allergy			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Pain			

subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Uterine Polyp			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic Obstructive Pulmonary Disease			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue Fever			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup Infectious			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious Mononucleosis			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus Infection			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Wound Infection			
subjects affected / exposed	0 / 139 (0.00%)	1 / 419 (0.24%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic Shock			
subjects affected / exposed	0 / 139 (0.00%)	0 / 419 (0.00%)	0 / 139 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 31 (0.00%)	2 / 94 (2.13%)	1 / 32 (3.13%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma Of The Cervix			



subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine Leiomyoma			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Exposure To Communicable Disease			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional Overdose			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratorhexis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament Injury			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple Fractures			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road Traffic Accident			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			

Hemiplegia			
subjects affected / exposed	0 / 31 (0.00%)	1 / 94 (1.06%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Ectopic Pregnancy			
subjects affected / exposed	0 / 31 (0.00%)	1 / 94 (1.06%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Imminent Abortion			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Food Allergy			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Uterine Polyp			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Chronic Obstructive Pulmonary Disease			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	1 / 32 (3.13%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue Fever			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup Infectious			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious Mononucleosis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus Infection			

subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Wound Infection			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic Shock			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase:Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 41 (0.00%)	3 / 128 (2.34%)	1 / 43 (2.33%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma Of The Cervix			
subjects affected / exposed	0 / 41 (0.00%)	1 / 128 (0.78%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine Leiomyoma			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	1 / 43 (2.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Exposure To Communicable Disease			

subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional Overdose			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratorhexis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ligament Injury			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple Fractures			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road Traffic Accident			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Hemiplegia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 41 (0.00%)	1 / 128 (0.78%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			

Ectopic Pregnancy			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Imminent Abortion			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Food Allergy			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal Pain			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Uterine Polyp			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	1 / 43 (2.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic Obstructive Pulmonary Disease			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			

Bronchitis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue Fever			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Croup Infectious			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious Mononucleosis			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus Infection			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 41 (0.00%)	1 / 128 (0.78%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative Wound Infection			
subjects affected / exposed	0 / 41 (0.00%)	0 / 128 (0.00%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic Shock			

subjects affected / exposed	0 / 41 (0.00%)	1 / 128 (0.78%)	0 / 43 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Primary Series: Cohort-1 Group 2: Verorab®	Primary Series: Cohort-1 Group 1: VRVg-2	Primary Series: Cohort-1 Group 3: Imovax Rabies®
Total subjects affected by non-serious adverse events			
subjects affected / exposed	121 / 202 (59.90%)	414 / 607 (68.20%)	128 / 200 (64.00%)
Nervous system disorders			
Headache			
subjects affected / exposed	50 / 202 (24.75%)	130 / 607 (21.42%)	47 / 200 (23.50%)
occurrences (all)	66	178	62
General disorders and administration site conditions			
Injection Site Pain			
subjects affected / exposed	95 / 202 (47.03%)	344 / 607 (56.67%)	106 / 200 (53.00%)
occurrences (all)	158	655	191
Malaise			
subjects affected / exposed	45 / 202 (22.28%)	161 / 607 (26.52%)	48 / 200 (24.00%)
occurrences (all)	57	229	79
Injection Site Swelling			
subjects affected / exposed	4 / 202 (1.98%)	14 / 607 (2.31%)	13 / 200 (6.50%)
occurrences (all)	4	19	18
Pyrexia			
subjects affected / exposed	12 / 202 (5.94%)	51 / 607 (8.40%)	5 / 200 (2.50%)
occurrences (all)	12	54	5
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	67 / 202 (33.17%)	249 / 607 (41.02%)	79 / 200 (39.50%)
occurrences (all)	103	405	135
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	9 / 202 (4.46%)	27 / 607 (4.45%)	12 / 200 (6.00%)
occurrences (all)	9	27	14



<b>Non-serious adverse events</b>	Primary Series: Cohort-2 Group 5: Verorab®	Primary Series: Cohort-2 Group 4: VRVg-2	Primary Series: Cohort-2 Group 6: Imovax Rabies®
Total subjects affected by non-serious adverse events subjects affected / exposed	34 / 139 (24.46%)	130 / 419 (31.03%)	48 / 139 (34.53%)
Nervous system disorders Headache subjects affected / exposed occurrences (all)	10 / 139 (7.19%) 14	40 / 419 (9.55%) 46	8 / 139 (5.76%) 9
General disorders and administration site conditions Injection Site Pain subjects affected / exposed occurrences (all)  Malaise subjects affected / exposed occurrences (all)  Injection Site Swelling subjects affected / exposed occurrences (all)  Pyrexia subjects affected / exposed occurrences (all)	30 / 139 (21.58%) 41  10 / 139 (7.19%) 14  0 / 139 (0.00%) 0  0 / 139 (0.00%) 0	111 / 419 (26.49%) 167  37 / 419 (8.83%) 43  1 / 419 (0.24%) 2  3 / 419 (0.72%) 3	43 / 139 (30.94%) 63  12 / 139 (8.63%) 16  1 / 139 (0.72%) 1  0 / 139 (0.00%) 0
Musculoskeletal and connective tissue disorders Myalgia subjects affected / exposed occurrences (all)	12 / 139 (8.63%) 17	78 / 419 (18.62%) 103	30 / 139 (21.58%) 38
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 139 (0.00%) 0	3 / 419 (0.72%) 3	0 / 139 (0.00%) 0

<b>Non-serious adverse events</b>	Booster Phase: Cohort-1 Group 2: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-1 Group 1: VRVg-2 (Primed With VRVg-2)	Booster Phase:Cohort-1 Group 3: VRVg-2 (Imovax Rabies®)
Total subjects affected by non-serious adverse events subjects affected / exposed	15 / 31 (48.39%)	48 / 94 (51.06%)	18 / 32 (56.25%)
Nervous system disorders Headache			

subjects affected / exposed occurrences (all)	3 / 31 (9.68%) 3	4 / 94 (4.26%) 4	7 / 32 (21.88%) 7
General disorders and administration site conditions			
Injection Site Pain			
subjects affected / exposed	12 / 31 (38.71%)	44 / 94 (46.81%)	17 / 32 (53.13%)
occurrences (all)	12	44	17
Malaise			
subjects affected / exposed	3 / 31 (9.68%)	8 / 94 (8.51%)	7 / 32 (21.88%)
occurrences (all)	3	8	7
Injection Site Swelling			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	9 / 31 (29.03%)	24 / 94 (25.53%)	15 / 32 (46.88%)
occurrences (all)	9	24	15
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 31 (0.00%)	0 / 94 (0.00%)	0 / 32 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Booster Phase: Cohort-2 Group 5: VRVg-2 (Verorab® Primed)	Booster Phase: Cohort-2 Group 4: VRVg-2 (Primed With VRVg-2)	Booster Phase: Cohort-2 Group 6: VRVg-2 (Imovax Rabies®)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 41 (4.88%)	21 / 128 (16.41%)	6 / 43 (13.95%)
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 41 (0.00%)	3 / 128 (2.34%)	0 / 43 (0.00%)
occurrences (all)	0	3	0
General disorders and administration site conditions			
Injection Site Pain			
subjects affected / exposed	2 / 41 (4.88%)	20 / 128 (15.63%)	6 / 43 (13.95%)
occurrences (all)	2	20	6

Malaise subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	5 / 128 (3.91%) 5	0 / 43 (0.00%) 0
Injection Site Swelling subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	0 / 128 (0.00%) 0	0 / 43 (0.00%) 0
Pyrexia subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	0 / 128 (0.00%) 0	0 / 43 (0.00%) 0
Musculoskeletal and connective tissue disorders Myalgia subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	10 / 128 (7.81%) 10	0 / 43 (0.00%) 0
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	0 / 128 (0.00%) 0	0 / 43 (0.00%) 0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 November 2021	Protocol amendment-2 was developed to conservatively adjust the estimation of seroconversion rate at Day (D)28 for adults subjects in VRVg-2 and the control vaccines from 99% to 96.5% according to the latest results from VAJ00001 study and to ensure the statistical power of the secondary objective to demonstrate that VRVg-2 is non-inferior to Verorab and Imovax Rabies vaccines in each age group (pediatric and adult population), in terms of proportion of subjects achieving an RVNA titer $\geq 0.5$ IU/mL at D28 based on the above-adjusted estimation. Protocol amendment 2 also incorporated a single booster between 2 and up to 3 years with a new batch of VRVg-2 as recommended in the new Advisory Committee on Immunization Practices (ACIP) 2021 guidelines.
31 May 2022	Protocol amendment-3 added a secondary objective to demonstrate the acceptability of the immune response at D28 of a 1-week 2-dose pre-exposure prophylaxis (PrEP) regimen. It also added the evaluation of persistence of the immune response at Month (M)6, M12, M18 and pre-booster between M24 up to M36 after a 2-dose primary series in the subset of adults who are randomized to be part of the Immunogenicity Persistence and Booster Phase Cohort 2.
17 November 2022	Protocol amendment-4: As stated in Section 1.3.1 (Potential Benefits to Subjects) of the protocol, most of the subjects were expected to have reached RVNA titers $\geq 0.5$ IU/mL after the completion of the 2- or 3-dose PrEP regimen of rabies vaccine (and booster dose for adult subsets). Depending on Investigator's clinical judgment, subjects with RVNA titers $< 0.5$ IU/mL at all timepoints, might be offered an additional injection of a local licensed rabies vaccine chosen by the Investigator and administered according to the local summaries of product characteristics (SmPC)/product label (PI) or national guidelines and if the subject / subject's legally acceptable representative (LAR) agreed. Such vaccine was offered outside of the scope of the protocol (i.e., no safety nor immunogenicity data were collected after this vaccine injection), free of charge at the study site. This was the Investigator's responsibility to decide which vaccine was the most appropriate for giving real benefit to the subject. Moreover, Section-5.2.9 (conditions for withdrawal) of the protocol was updated to avoid any unnecessary subjects' withdrawal due to missing visits (at M6, M12, and/or M18) during the Immunogenicity Persistence and Booster Phase Cohort 2 (adult subset). Section-6.7 (randomization and allocation procedures) of the protocol was updated to clarify the subject number assigning rule was different between Cohort 1 and Cohort 2, due to different interactive response technology (IRT) settings.
12 June 2023	Protocol amendment-5 added 2 secondary objectives to demonstrate the non-inferiority (NI) of a 2-dose VRVg-2 PrEP at D28 versus 3-dose Imovax Rabies PrEP at D42 in each age group, and also to demonstrate NI of 2-dose Imovax Rabies PrEP at D28 versus 3-dose Imovax Rabies PrEP at D42 in the overall subjects, both with a NI margin of -10%for each of these 2 new secondary objectives.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported